Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Editorial50th Anniversary Celebration Collection Special Section on Perspectives on Drug Metabolism and Disposition, Part I—Editorial

Special Section on Perspectives on Drug Metabolism and Disposition, Part I—Editorial

Yurong Lai and Xinxin Ding
Drug Metabolism and Disposition June 2023, 51 (6) 645-646; DOI: https://doi.org/10.1124/dmd.123.001352
Yurong Lai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yurong Lai
  • For correspondence: yurong.lai@gilead.com
Xinxin Ding
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

The “Perspectives on Drug Metabolism and Disposition” special section features articles contributed by the current associate editors of Drug Metabolism and Disposition (DMD) to the 50th Anniversary Celebration Collection (Ding, 2023). The Collection already includes a number of articles (Ding, 2023; Gillam and Kramlinger, 2023; Guengerich, 2023; Isin, 2023; McColl et al., 2023; Morgan et al., 2023; Roberts et al., 2023; Yamazaki and Shimizu, 2023), with many more to come.

The special section of Perspectives on Drug Metabolism and Disposition is divided into two parts. In Part I, five of our esteemed colleagues provide their perspectives on specific subjects in their areas of expertise.

Human absorption, distribution, metabolism, and excretion (ADME) studies hold immense significance as they provide a comprehensive and quantitative understanding of the overall disposition of a drug candidate in humans. A review article authored by Dr. R. Scott Obach, one of the Most Prolific Authors in DMD (Ding, 2023), and his colleagues at Pfizer, Inc., entitled “Human absorption, distribution, metabolism, and excretion studies: origins, innovations, and importance” (Cerny et al., 2023), offers a historical perspective on the origins of ADME studies and their advancements that have taken place since the pioneering work of George de Hevesy, who earned the 1943 Nobel Prize in Chemistry. The paper highlights the fact that DMD has served as an essential platform for the dissemination of ADME study findings for the past 5 decades. The article also delivers a comprehensive background on the progress of human ADME studies and technological advancements, describing the impact of technological and instrumental breakthroughs on the approaches used at different times for conducting human ADME studies and showcasing the ongoing debate concerning the significance of animal ADME studies versus a “human-first, human-only strategy.”

Pollutant chemicals can interfere with the normal functions of hormones, which play a critical role in controlling liver xenobiotic-metabolizing enzymes, such as cytochromes P450s. Dr. David S. Riddick of the University of Toronto studies how hormones produced by the pituitary and adrenal glands affect an organism's sensitivity to the toxic effects of polycyclic aryl hydrocarbons by modulating the aryl hydrocarbon receptor (AhR) signaling pathway and the mechanisms by which AhR-activating chemicals disrupt endocrine pathways, resulting in down-regulated expression and function of hepatic P450s. In his review article “Fifty years of aryl hydrocarbon receptor research as reflected in the pages of drug metabolism and disposition” (Riddick, 2023), Dr. Riddick provides a decade-by-decade summary of significant historical discoveries in the AhR field and recognizes the numerous contributions made by publications featured in DMD. The article inspires present and future researchers in the AhR field by taking a historical journey through these landmark studies.

Dr. Xiao-bo Zhong and a colleague from the University of Connecticut reviewed the emergent topic of epigenetic regulation of gene expression in their article titled “Epigenetic mechanisms contribute to intraindividual variations of drug metabolism mediated by cytochrome P450 enzymes” (Jin and Zhong, 2023). Genetic polymorphisms primarily cause interindividual differences, whereas epigenetic mechanisms, including DNA methylation, histone modifications, microRNAs, and long noncoding RNAs contribute additionally to intraindividual variations. In this paper, Dr. Zhong and his colleague provide an in-depth analysis of the latest advancements in this area in the past decade and the contributions of various types of epigenetic modifications to intraindividual variations in cytochrome P450–mediated drug metabolism. The article highlights the role of epigenetic mechanisms in regulating drug metabolism within individuals, including the potential impact of epigenetic modifications on the expression of drug- metabolizing enzymes during development or by environmental exposures and drug treatments.

Dr. Aiming Yu of the University of California Davis is an expert on drug metabolism interested in noncoding RNAs, anticancer pharmacology, pharmacokinetics, pharmacodynamics, and experimental therapeutics. His laboratory has been exploring cutting-edge RNA bioengineering technologies for investigating the mechanisms by which microRNAs regulate cellular processes, including metabolism and the progression and metastasis of tumors, to create innovative therapies. The review article contributed by Dr. Yu and his colleague, titled “Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research,” summarizes the various recombinant DNA technologies that enable researchers to produce almost any ADME gene product for functional and structural analyses to study drug metabolism and pharmacokinetics (Cronin and Yu, 2023). The article presents an overview of the latest RNA technologies and the potential utilities of bioengineered RNA agents in investigating ADME gene regulation and other areas of biomedical research.

Finally, Dr. Nina Isoherranen and colleagues at the University of Washington discuss the “Impact of intracellular lipid binding proteins (iLBPs) on endogenous and xenobiotic ligand metabolism and disposition” (Yabut and Isoherranen, 2023). They performed an in-depth review of various aspects of iLBPs related to these proteins' potential contributions to xenobiotic distribution and metabolism, including tissue-specific expression and functions, ligand binding characteristics, known endogenous and xenobiotic ligands, and mechanisms of delivering ligands to membranes and enzymes. They also describe the methods for measuring ligand binding and available evidence supporting the potential importance of iLBPs in modulating xenobiotic disposition. The review pays particular attention to fatty acid binding proteins, which constitute the bulk of iLBPs and can bind many types of drugs, such as nonsteroidal anti-inflammatory drugs, cannabinoids, benzodiazepines, antinociceptives, and peroxisome proliferators. It suggests the need to assess drug binding to the fatty acid binding proteins more regularly as is done for serum albumin binding.

DMD covers a broad range of topics as listed in our Instructions for Authors (https://dmd.aspetjournals.org/content/ifora#Scope_of_Submited_Manuscripts). The articles in this special section highlight only a few topics and historical perspectives in the drug metabolism and disposition field. Additional topics will be discussed in Part II and other future special sections.

Footnotes

    • Received April 4, 2023.
    • Accepted April 4, 2023.
  • dx.doi.org/10.1124/dmd.123.001352.

  • Copyright © 2023 by The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Cerny MA,
    2. Spracklin DK, and
    3. Obach RS
    (2023) Human Absorption, Distribution, Metabolism and Excretion Studies - Origins, Innovations and Importance. Drug Metab Dispos 51:685–699.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Cronin J and
    2. Yu AM
    (2023) Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research. Drug Metab Dispos 51:647–656.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Ding X
    (2023) Celebrating 50 Years of Excellence in DMD Science. Drug Metab Dispos 51:96–98.
    OpenUrl
  4. ↵
    1. Gillam EMJ and
    2. Kramlinger VM
    (2023) Opportunities for Accelerating Drug Discovery and Development by Using Engineered Drug-Metabolizing Enzymes. Drug Metab Dispos 51:392–402.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Guengerich FP
    (2023) Drug Metabolism: A Half-Century Plus of Progress, Continued Needs, and New Opportunities. Drug Metab Dispos 51:99–104.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Isin EM
    (2023) Unusual Biotransformation Reactions of Drugs and Drug Candidates. Drug Metab Dispos 51:413–426.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Jin J and
    2. Zhong XB
    (2023) Epigenetic Mechanisms Contribute to Intraindividual Variations of Drug Metabolism Mediated by Cytochrome P450 Enzymes. Drug Metab Dispos 51:672–684.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. McColl ER,
    2. Croyle MA,
    3. Zamboni WC,
    4. Honer WG,
    5. Heise M,
    6. Piquette-Miller M, and
    7. Goralski KB
    (2023) COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics. Drug Metab Dispos 51:130–141.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Morgan ET,
    2. Novak RF,
    3. Halpert JR,
    4. Johnson EF, and
    5. Stevens JC
    (2023) The Evolution of Drug Metabolism and Disposition: A Perspective From the Editors. Drug Metab Dispos 51:105–110.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Riddick DS
    (2023) Fifty years of aryl hydrocarbon receptor research as reflected in the pages of Drug Metabolism and Disposition. Drug Metab Dispos 51:657–671.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Roberts AG,
    2. Stevens JC,
    3. Szklarz GD,
    4. Scott EE,
    5. Kumar S,
    6. Shah MB, and
    7. Halpert JR
    (2023) Four Decades of Cytochrome P450 2B Research: From Protein Adducts to Protein Structures and Beyond. Drug Metab Dispos 51:111–122.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Yabut KCB and
    2. Isoherranen N
    (2023) Impact of Intracellular Lipid Binding Proteins on Endogenous and Xenobiotics Ligand Metabolism and Disposition. Drug Metab Dispos 51:700–717.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Yamazaki H and
    2. Shimizu M
    (2023) Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes. Drug Metab Dispos 51:123–129.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 51 (6)
Drug Metabolism and Disposition
Vol. 51, Issue 6
1 Jun 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Special Section on Perspectives on Drug Metabolism and Disposition, Part I—Editorial
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Editorial50th Anniversary Celebration Collection Special Section on Perspectives on Drug Metabolism and Disposition, Part I—Editorial

Editorial for Perspectives on Drug Metabolism and Disposition

Yurong Lai and Xinxin Ding
Drug Metabolism and Disposition June 1, 2023, 51 (6) 645-646; DOI: https://doi.org/10.1124/dmd.123.001352

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Editorial50th Anniversary Celebration Collection Special Section on Perspectives on Drug Metabolism and Disposition, Part I—Editorial

Editorial for Perspectives on Drug Metabolism and Disposition

Yurong Lai and Xinxin Ding
Drug Metabolism and Disposition June 1, 2023, 51 (6) 645-646; DOI: https://doi.org/10.1124/dmd.123.001352
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics